Volume 66, Issue 6, Pages 1190-1193 (December 2014) Re: Antibody-drug Conjugates Targeting Prostate-specific Membrane Antigen Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Roberta Mazzucchelli, Francesco Montorsi European Urology Volume 66, Issue 6, Pages 1190-1193 (December 2014) DOI: 10.1016/j.eururo.2014.08.047 Copyright © 2014 Terms and Conditions
Fig. 1 (a) Strong and diffuse prostate-specific antigen (PSA) immunostaining in a Gleason 3+3=6 acinar adenocarcinoma; (b) lack of PSA immunostaining in the bone metastasis of a solid prostate cancer (this represents the progression stage of the patient whose initial adenocarcinoma is shown in (a); (c) weak and focal prostate-specific membrane antigen (PSMA) immunostaining (the same tumor as in [a]); (d) strong and diffuse PSMA immunostaining, mostly at the cell membrane level (the same tumor as in [b]). European Urology 2014 66, 1190-1193DOI: (10.1016/j.eururo.2014.08.047) Copyright © 2014 Terms and Conditions